RT BBC Breaking News (@BBCBreaking)"Ketamine Queen" who sold drugs to actor Matthew Perry before his overdose death sentenced to 15 years https://t.co/EhQU5lrRFu ...

Drugs targeting a specific protein could make for powerful treatments for chronic pain, according to a new study. Even diet might have an effect https://t.co/hRibKlhEd4 ...

Drugs targeting a specific protein could make for powerful treatments for chronic pain, according to a new study. Even diet might have an effect https://t.co/VpMCUZ3o3m ...

Drugs targeting a specific protein could make for powerful treatments for chronic pain, according to a new study. Even diet might have an effect https://t.co/gQepfmVIyK ...

Core Insights - Interest in phased retirement programs is increasing, although formal programs remain rare in the workplace [3][4] - A significant portion of the workforce, particularly older employees, is seeking options for gradual transition out of the workforce [4][5] Company Insights - Abbott offers a "Freedom to Work" program for employees aged 55 and older with over 10 years of service, allowing for reduced work schedules or additional time off [8] - The phased retirement program at Abbott is designed to help employees transition into retirement at their own pace [1] Industry Insights - Only 7% of firms surveyed by the Society for Human Resource Management (SHRM) provide formal phased retirement programs, while about 20% offer informal options [2] - Many older workers are financially unprepared for retirement and prefer to continue working, often delaying retirement due to financial necessity [5][6]

Market Overview - US stock futures increased slightly, with Dow Jones Industrial Average futures up 0.2%, S&P 500 contracts also rising 0.2%, and Nasdaq 100 futures gaining 0.3% [1] - Oil prices fell approximately 7% following President Trump's comments about a potential quick end to the Iran conflict, with West Texas Intermediate crude at about $88 per barrel and Brent crude around $92 [4] Corporate Earnings - Oracle is set to report its fourth-quarter earnings, with its stock rising 2% in premarket trading [6] - Adobe is scheduled to release its earnings on Thursday [5] - Hewlett Packard Enterprise reported a revenue beat for Q2, driven by strong demand for AI infrastructure, and raised its fiscal 2026 adjusted earnings per share forecast to $2.30-$2.50 [7][8] - Vertex Pharmaceuticals' stock rose 4% after announcing positive results from a late-stage trial for a drug treating a rare kidney disease [6] Oil Market Dynamics - The conflict in Iran has led to hardliners rallying behind new leadership, which may complicate the situation regarding tanker traffic through the Strait of Hormuz [3] - Saudi Aramco's management indicated that operations are normal and that they can ramp up oil shipments quickly once the Strait of Hormuz stabilizes [10]

Core Insights - The findings have been tested in the real world, indicating practical applicability and relevance to current market conditions [1] Group 1 - The research emphasizes the importance of real-world testing for validating theoretical models [1]

Company Performance - Abbott's stock closed at $115.29, reflecting a +2.74% change from the previous day's closing price, outperforming the S&P 500 which lost 1.04% [1] - Over the past month, Abbott's shares gained 4.46%, surpassing the Medical sector's gain of 0.7% and the S&P 500's gain of 1.75% [1] Upcoming Earnings - Abbott is expected to report an EPS of $1.15, representing a 5.5% increase from the prior-year quarter, with revenue estimated at $11.03 billion, indicating a 6.53% increase year-over-year [2] - For the full year, analysts project earnings of $5.68 per share and revenue of $47.73 billion, marking changes of +10.29% and +7.67% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Abbott reflect shifting business dynamics, with positive revisions indicating analysts' confidence in the company's performance and profit potential [4] - The Zacks Consensus EPS estimate has increased by 0.16% over the past month, and Abbott currently holds a Zacks Rank of 3 (Hold) [6] Valuation Metrics - Abbott has a Forward P/E ratio of 19.76, which is lower than the industry average of 20.25, indicating that Abbott is trading at a discount compared to its peers [7] - The company has a PEG ratio of 1.79, aligning with the average PEG ratio of the Medical - Products industry [7] Industry Context - The Medical - Products industry, to which Abbott belongs, has a Zacks Industry Rank of 140, placing it in the bottom 43% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Viewpoint - Healthcare is perceived as a defensive sector, maintaining stability in revenue generation even when technology stocks are volatile and consumer spending fluctuates [1] Group 1 - Healthcare companies continue to sell drugs, perform surgeries, and process insurance claims regardless of market conditions [1]

Group 1 - The importance of stock valuation for long-term returns is emphasized, indicating that even great companies can yield limited returns if purchased at a high premium [1] - A reliable method to assess a stock's value is through its forward price-to-earnings (P/E) ratio, which reflects expected earnings for the upcoming year, as opposed to trailing P/E [2] Group 2 - AbbVie has a forward P/E of just under 16, significantly lower than the S&P 500 average of 22, and a PEG ratio of around 0.40, indicating it is a strong buy [4][9] - AbbVie reported revenue of $44.5 billion for the first nine months of the year, an 8% increase year-over-year, with operating earnings of $10.5 billion, positioning it for high single-digit growth through the end of the decade [6] Group 3 - Micron Technology's shares have increased by approximately 250% in the past year, yet it maintains a forward P/E of 11 and a PEG ratio of 0.6, suggesting it remains undervalued [7] - The company is shifting focus from its consumer business to business-to-business operations due to high demand for memory and storage products, driven by tech investments in data centers and AI [8]